8-K: Surrozen Announces First Quarter 2024 Financial Results and Provides Business Update

Surrozen reported its first quarter 2024 financial results, highlighting progress in clinical trials and research programs, and a recent financing that boosted its cash position.

Summary

• Surrozen released its financial results for the first quarter of 2024, showing a net loss of $8.8 million, an improvement from the $14.3 million loss in the same period of 2023.
• The company's cash and cash equivalents were $27.3 million as of March 31, 2024, but pro forma cash, including proceeds from an April 2024 financing, was $43.2 million.
• Research and development expenses decreased to $5.2 million from $8.1 million year-over-year, primarily due to restructuring efforts.
• General and administrative expenses also decreased to $3.9 million from $5.3 million year-over-year, also due to restructuring.
• The company completed a Phase 1a study for SZN-043 in February 2024 and expects to begin enrollment for a Phase 1b study in the second quarter of 2024, with proof-of-concept data anticipated in the first half of 2025.
• Surrozen presented preclinical data at ARVO 2024, demonstrating the potential of their antibody-based Wnt mimetic for treating severe eye diseases.
• A partnership with Boehringer Ingelheim for SZN-413 is progressing, with a potential $10 million milestone payment expected in 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with improved financial results and progress in clinical trials, although the company is still operating at a loss. The recent financing and partnership milestones are encouraging.

Positives

• The company's net loss decreased significantly year-over-year, indicating improved financial performance.
• The pro forma cash position is strong, providing financial stability for ongoing research and development.
• The decrease in operating expenses reflects successful restructuring efforts.
• The completion of the Phase 1a study for SZN-043 and the planned initiation of the Phase 1b study are positive steps in clinical development.
• Preclinical data suggests the potential of Surrozen's technology in treating severe eye diseases.
• The partnership with Boehringer Ingelheim is progressing, with a potential milestone payment expected.

Negatives

• The company still reported a net loss of $8.8 million for the quarter.
• Cash and cash equivalents decreased from $36.0 million at the end of 2023 to $27.3 million at the end of Q1 2024, before the April financing.

Risks

• The company's ability to fund its clinical trials and development efforts is dependent on existing funds and potential future fundraising.
• The success of clinical trials and the development of drug candidates are subject to various risks and uncertainties.
• The company's financial performance is subject to volatility in global economic, political, regulatory, and market conditions.
• There is a risk that actual results could differ materially from the forward-looking statements.

Future Outlook

Surrozen expects 2024 to be an important year focused on advancing the SZN-043 Phase 1b trial and communicating data from key R&D programs. The company anticipates proof-of-concept data from the SZN-043 Phase 1b trial may be available in the first half of 2025. They also anticipate a potential $10 million milestone payment from Boehringer Ingelheim in 2024.

Management Comments

• Craig Parker, President and Chief Executive Officer of Surrozen, stated that 2024 is expected to be an important year focused on advancing the SZN-043 Phase 1b trial and communicating data from key R&D programs.
• Surrozen remains driven to transform the treatment of severe diseases of the liver and eye, where we believe Wnt modulation plays an essential role.

Industry Context

Surrozen is operating in the competitive biotechnology sector, focusing on Wnt pathway modulation for tissue repair and regeneration. The company's focus on liver and eye diseases aligns with areas of significant unmet medical need. The partnership with Boehringer Ingelheim highlights the potential of their technology and the interest from larger pharmaceutical companies.

Comparison to Industry Standards

• Surrozen's decrease in R&D spending is not uncommon for companies that have undergone restructuring, as they focus on core programs.
• The company's cash burn rate is typical for a clinical-stage biotech company, and the recent financing is crucial for continued operations.
• The partnership with Boehringer Ingelheim is similar to other biotech collaborations, where smaller companies license their technology to larger firms for development and commercialization.
• The anticipated milestone payment of $10 million is a standard practice in biotech partnerships.
• Companies like Regulus Therapeutics and Dicerna Pharmaceuticals are also working on RNA-based therapies for liver diseases, and Surrozen's approach using Wnt modulation is a different but potentially competitive strategy.
• In the eye disease space, companies like REGENXBIO and Adverum Biotechnologies are developing gene therapies, while Surrozen is focusing on antibody-based Wnt mimetics, offering a different approach to treatment.

Stakeholder Impact

• Shareholders will be encouraged by the improved financial results and progress in clinical trials.
• Employees may benefit from the company's continued growth and development.
• Patients with severe liver and eye diseases may benefit from the potential development of new treatments.
• The partnership with Boehringer Ingelheim could lead to further investment and growth for the company.

Next Steps

• Surrozen will begin enrollment for the Phase 1b study of SZN-043 in the second quarter of 2024.
• The company will continue to advance its research and development programs.
• Surrozen anticipates the potential to nominate the lead Fzd-4 targeted Wnt agonist development candidate in 2024.
• The company will present SZN-043 Phase 1a clinical trial results at the 2024 European Association for the Study of the Liver (EASL) in Milan.

Key Dates

Keywords

Wnt pathway, SZN-043, SZN-413, clinical trials, liver disease, eye disease, biotechnology, Boehringer Ingelheim, research and development, financial results